Swedish immuno-oncology firm BioInvent (OMXS: BINV) and New York pharma major Pfizer (NYSE: PFE) have extended their ongoing collaboration, through to the end of the year.
Following the original December 2016 agreement, Lund-based BioInvent has been using its F.I.R.S.T drug discovery platform to identify antibodies targeting tumor-associated myeloid cells.
Pfizer has already selected the first and second targets under the agreement, and the extension will allow further targets and antibodies to be characterized.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze